The phosphoinositide 3-kinase (PI3K) signaling pathway has been highly implicated in human prostate cancer on the basis of frequent loss of the tumor suppressor gene, PTEN in advanced disease. PTEN encodes a phosphatase that hydrolyzes the lipid product of PI3K, phosphatidylinositol-3,4,5-trisphosphate and loss of PTEN results in hyperactivation of the protein-Ser/Thr kinase AKT as well as other effectors of the PI3K pathway. In this project, we propose to further elucidate components of the PI3K pathway that contribute to prostate cancer. In addition, we propose to manipulate endogenous PI3K and PTEN genes and introduce oncogenic mutations of PI3K into mice in order to test the necessity and sufficiency of PI3K isoforms for development of prostate cancer. This project has three specific aims.
Aim 1 : We will attempt to identify upstream activators of PI3K in human prostate cancer cell lines and in xenograph models by immunoprecipitating PI3K and identifying co-precipitating proteins. The results of this study should reveal protein-Tyr kinase activators of PI3K that contribute to prostate cancer and that could be targeted for therapeutic intervention.
Aim 2 : We will introduce oncogenic mutants of the p110a subunit of PI3K into prostate epithelial tissue by transgene and knockin approaches and determine the effect of these mutations on prostate neoplasia and on gene expression profiles. The results of this study will be compared to our previous results with PTEN deletions and with results from mouse models being developed in the Sellers' laboratory (Project 2) and Sawyers' laboratory (Project 3) where activated genes for components downstream of the PI3K pathway are being introduced into the prostate.
Aim 3 : We will introduce a drug- inducible dominant negative form of PI3K to determine the effect of acute inhibition of this pathway on prostate tumors that develop due to loss of PTEN. In addition, we will delete specific genes for catalytic and regulatory subunits of class IA PI3K family in the prostate in the context of prostate-specific PTEN deletion in order to determine which isoforms of PI3K are critical for tumor formation. The results of this study will predict whether drugs that target specific PI3K isoforms will be effective in treating this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA089021-07
Application #
7683299
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
7
Fiscal Year
2008
Total Cost
$455,968
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Patnaik, Akash; Swanson, Kenneth D; Csizmadia, Eva et al. (2017) Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov 7:750-765
Lee, So Jin; Kim, Min Ju; Kwon, Ick Chan et al. (2016) Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev 104:2-15
Martin, Neil E; Gerke, Travis; Sinnott, Jennifer A et al. (2015) Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res 13:1431-40
González-Billalabeitia, Enrique; Seitzer, Nina; Song, Su Jung et al. (2014) Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 4:896-904
Flavin, Richard; Pettersson, Andreas; Hendrickson, Whitney K et al. (2014) SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 20:4904-11
Selvarajah, Shamini; Pyne, Saumyadipta; Chen, Eleanor et al. (2014) High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res 20:1521-30
Ittmann, Michael; Huang, Jiaoti; Radaelli, Enrico et al. (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73:2718-36
Chen, Sen; Jiang, Xinnong; Gewinner, Christina A et al. (2013) Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal 6:ra40
Jia, Shidong; Gao, Xueliang; Lee, Sang Hyun et al. (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3:44-51
Polkinghorn, William R; Parker, Joel S; Lee, Man X et al. (2013) Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3:1245-53

Showing the most recent 10 out of 94 publications